Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials^*

References

• Mehta SR, Yusuf S, Peters RJ, . Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358:527–33
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT 3rd, . Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288:2411–20
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM, . Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005; 294:1224–32
   PubMed Web of Science ®Google Scholar
• Lindgren P, Stenestrand U, Malmberg K, . The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden. Clin Ther 2005; 27:100–10
   PubMed Web of Science ®Google Scholar
• Ringborg A, Lindgren P, Jonsson B. The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. Eur J Health Econ 2005; 6:354–6, 8–62
   PubMedGoogle Scholar
• Detsky AS, Naglie G, Krahn MD, . Primer on medical decision analysis: Part 2 – Building a tree. Med Decis Making 1997; 17:126–35
   PubMed Web of Science ®Google Scholar
• Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13:322–38
   PubMed Web of Science ®Google Scholar
• Hospital Discharge Register and Cause of Death Register. Swedish National Board of Health and Welfare, 1995–2003
   Google Scholar
• Yusuf S, Zhao F, Mehta SR, . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494–502
   PubMed Web of Science ®Google Scholar
• Systematic Reviews in Health Care: Meta-analysis in Context, 2nd edn. London: BMJ Publishing Group, 2001
   Google Scholar
• Zethraeus N, Molin T, Henriksson P, . Costs of coronary heart disease and stroke: the case of Sweden. J Intern Med 1999; 246:151–9
   PubMed Web of Science ®Google Scholar
• Levy E, Gabriel S, Dinet J. The comparative medical costs of atherothrombotic disease in European countries. Pharmacoeconomics 2003; 21:651–9
   PubMed Web of Science ®Google Scholar
• Rossnagel K, Nolte CH, Muller-Nordhorn J, . Medical resource use and costs of health care after acute stroke in Germany. Eur J Neurol 2005; 12:862–8
   PubMed Web of Science ®Google Scholar
• Johannesson M. The cost effectiveness of hyper-tension treatment in Sweden. Pharmacoeconomics 1995; 7:242–50
   PubMed Web of Science ®Google Scholar
• Bruggenjurgen B, Rupprecht H-J, Willich SN, . Cost of atherothrombotic diseases - myocardial infarction, ischaemic stroke and peripheral arterial occlusive disease – in Germany. J Public Health 2005; 13:216–24
   Google Scholar
• Kolominsky-Rabas PL, Heuschmann PU, . Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project. Stroke 2006; 37:1179–83
   PubMed Web of Science ®Google Scholar
• Spieler JF, Lanoe JL, Amarenco P. Costs of stroke care according to handicap levels and stroke subtypes. Cerebrovasc Dis 2004; 17:134–42
   PubMed Web of Science ®Google Scholar
• Drummond M, Sculpher M, Torrance G. Methods for the economic evaluation of health care programmes, 3rd. Oxford: Oxford University Press, 2005
   Google Scholar
• General guidelines for economic evaluations from the Pharmaceutical Benefits Board. 2003. [cited LFNAR 2003:2; Available from: http://www.lfn.se/LFNTemplates/Page____442.aspx
   Google Scholar
• Burstrom K, Johannesson M, Diderichsen F. Health-related quality of life by disease and socio-economic group in the general population in Sweden. Health Policy 2001; 55:51–69
   PubMed Web of Science ®Google Scholar
• Lindgren P, Graff J, Olsson AG, . Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin. Eur Heart J 2007; 28:1448–53
   PubMed Web of Science ®Google Scholar
• Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 1997; 16:33–64
   PubMed Web of Science ®Google Scholar
• Ekman M. Consumption and Production by Age in Sweden: Basic Facts and Health Economic Implications. Studies in Health Economics Modelling and Data Analysis of Costs and Survival Dissertation. For the degree of Doctor of Philosophy at the Stockholm School of EconomicsStockholm: EFI, 2002
   Google Scholar
• Human Mortality Database. 6 Feb 2007, 2003. [cited 6 February 2007]; Available from: http://www.mortality.org
   Google Scholar
• Lothgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 2000; 9:623–30
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557–60
   PubMed Web of Science ®Google Scholar
• Yusuf S, Mehta SR, Zhao F, . Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003; 107:966–72
   PubMed Web of Science ®Google Scholar
• Eichler HG, Kong SX, Gerth WC, . Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7:518–28
   PubMed Web of Science ®Google Scholar
• Socialstyrelsens riktlinjer för hjärtsjukvård. Beslutsstöd för prioriteringar. Swedish National Board of Health and Welfare 2004
   Google Scholar
• Armstrong PW, Fu Y, Chang WC, . Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation 1998; 98:1860–8
   PubMed Web of Science ®Google Scholar
• Singh M, Reeder GS, Jacobsen SJ, . Scores for post-myocardial infarction risk stratification in the community. Circulation 2002; 106:2309–14
   PubMed Web of Science ®Google Scholar
• Fitchett D. The impact of bleeding in patients with acute coronary syndromes: how to optimize the benefits of treatment and minimize the risk. Can J Cardiol 2007; 23:663–71
   PubMed Web of Science ®Google Scholar
• FASS. February 2007, 2006. [cited 6 February 2007]; Available from: http://www.fass.se
   Google Scholar
• Gelbe Liste Pharmindex. 6 February 2007, 2006. [cited 6 February 2007]; Available from: http://www.gelbe-liste.de/01_start/index.html
   Google Scholar
• Kostnad per patient databasen. 2006. [cited 6 February 2007]; Available from: http://www.skl.se/bunt.asp?C=1334
   Google Scholar